ArticleFrontiers in oncology2020
Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Integrating network toxicology with multi-omics approaches to elucidate molecular targets and pathway mechanisms in BPA-induced hepatocellular carcinoma.Molecular diversity · 2026Article
- Impact of Clonal Hematopoiesis of Indeterminate Potential on Treatment Response and Tumor Microenvironment in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Journal of mammary gland biology and neoplasia · 2026Article
- A population-based analysis of a risk stratification system for predicting radiotherapy benefits in invasive breast carcinoma of no special type with medullary pattern.European journal of medical research · 2025Article
- Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Prognostic value and immune infiltration of a tumor microenvironment-related PTPN6 in metastatic melanoma.Cancer cell international · 2024Article
- High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.Contemporary oncology (Poznan, Poland) · 2024Article
- Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures.Nature communications · 2023Article
- Immunotherapy: Constructive Approach for Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2023Review
- Breast cancer mortality as a function of age.Aging · 2022Article
- An RNA-binding protein-related risk signature can predict the prognosis and tumor immunity of patients with testicular germ cell tumors.American journal of translational research · 2022Article
- Toll-like receptor 2 (TLR2) is a candidate prognostic factor in testicular germ cell tumors as well as an indicator of immune function in the tumor microenvironment.Bioengineered · 2021Article
- Metabolic regulation in the immune response to cancer.Cancer communications (London, England) · 2021Review
- A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.BMC cancer · 2021Article
- Using immune-related lncRNAs to construct novel biomarkers and investigate the immune landscape of breast cancer.Translational cancer research · 2021Article
- Identification of a Prognostic Signature Model with Tumor Microenvironment for predicting Disease-free Survival after Radical Prostatectomy.Journal of Cancer · 2021Article
- A Signature of Autophagy-Related Long Non-coding RNA to Predict the Prognosis of Breast Cancer.Frontiers in genetics · 2021Article
- Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell Genotypes and Stroke Risk in Breast Cancer Microenvironment.Oxidative medicine and cellular longevity · 2021Article
- Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors.International journal of general medicine · 2021Article
- Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.Journal of translational medicine · 2020Article
- Construction of a risk signature for adrenocortical carcinoma using immune-related genes.Translational andrology and urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is a heterogeneous system that contributes to breast cancer progression. The Cancer Genome Atlas (TCGA) database provides global gene expression profiling data for further analysis of various malignancies, including breast cancer. Based on the ESTIMATE algorithm, immune and stromal scores were calculated according to immune or stromal components in the TME. We divided breast cancer cases into high- and low-score groups and identified differentially expressed genes (DEGs) that were significantly associated with overall survival. We performed enrichment analysis and constructed a protein-protein interaction network and found that the DEGs were mainly involved in primary immunodeficiency, T cell receptor signaling pathway and cytokine-cytokine receptor reaction. Furthermore, we explored the effect of aging on immune and stromal scores, which was validated by lower immune/stromal scores, lower infiltration of T cells and lower expression of immune checkpoints in the elder group. In conclusion, certain differentially expressed immune-related genes contribute to longer overall survival, and aging influences the immune microenvironment and immunotherapy efficacy by changing the tumor-infiltrating lymphocyte (TIL) abundance and checkpoint expression in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.